Natriuretic peptide hormone measurement in acute coronary syndromes.
Cardiac Ischemia is an important trigger for the release of B-type natriuretic peptide (BNP). BNP and N-terminal pro-BNP (N-proBNP) are emerging as important biomarkers for risk stratification in patients with acute coronary syndromes. Higher levels of BNP and pro-BNP are associated with a greater risk for death and heart failure, independent of traditional clinical variables and levels of other biomarkers such as troponins and C-reactive protein. The therapeutic implications of these findings are not yet known.
Donald W. Reynolds Cardiovascular Clinical Research Center and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Param
P
Maewal
James A
JA
de Lemos
D000208:Acute Disease; D001681:Biological Assay; D015415:Biomarkers / Q000032:analysis; D003327:Coronary Disease / Q000175:diagnosis*; D006333:Heart Failure / Q000175:diagnosis; D006801:Humans; D009203:Myocardial Infarction / Q000175:diagnosis; D017202:Myocardial Ischemia / Q000175:diagnosis; D020097:Natriuretic Peptide, Brain / Q000032:analysis*; D011379:Prognosis; D018570:Risk Assessment
D015415:Biomarkers; D020097:Natriuretic Peptide, Brain